M&A
confidence high
sentiment positive
materiality 0.75
Eton acquires Galzin (zinc acetate) for $7.2M; rare disease product for Wilson Disease
Eton Pharmaceuticals, Inc.
- Acquired Galzin from Teva Pharmaceuticals for $7.0M at closing plus $0.2M for inventory.
- Will pay Teva a 10% royalty on U.S. net sales through the tenth anniversary of first commercial sale.
- Galzin is the only FDA-approved zinc maintenance therapy for Wilson Disease; <5,000 U.S. patients.
- Eton expects to assume U.S. commercialization in Q1 2025 with its metabolic sales force.
- Also acquired European rights; third party commercializes under Wilzin with Eton supplying product.